Edition:
United States

ImmuCell Corp (ICCC.OQ)

ICCC.OQ on NASDAQ Stock Exchange Capital Market

5.52USD
2:11pm EDT
Change (% chg)

$-0.04 (-0.72%)
Prev Close
$5.56
Open
$5.61
Day's High
$5.61
Day's Low
$5.52
Volume
905
Avg. Vol
2,015
52-wk High
$8.22
52-wk Low
$4.90

ICCC.OQ

Chart for ICCC.OQ

About

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle,... (more)
No analyst recommendations are available for ICCC.OQ.

Overall

Beta: 0.73
Market Cap(Mil.): $27.46
Shares Outstanding(Mil.): 4.85
Dividend: --
Yield (%): --

Financials

  ICCC.OQ Industry Sector
P/E (TTM): 44.65 48.09 29.63
EPS (TTM): 0.13 -- --
ROI: -- -2.54 13.01
ROE: -- 5.17 14.16

BRIEF-ImmuCell says secures $2 million in debt financing

* ImmuCell secures $2 million in debt financing Source text for Eikon: Further company coverage:

Mar 02 2017

BRIEF-Immucell Q4 sales fell 18 pct

* Q4 sales fell 18 percent to $2.2 million Source text for Eikon: Further company coverage:

Feb 09 2017

BRIEF-Immucell files for sale of up to 659,880 shares of co's common stock

* Files for sale of up to 659,880 shares of co's common stock by selling stockholders - sec filing

Nov 16 2016

BRIEF-ImmuCell to raise $3.5 mln in private placement

* Says co agreed to sell an aggregate total of 659,880 shares of common stock at a price of $5.25 per share to outside investors

Oct 18 2016

BRIEF-Immucell Corp sees FDA approval for Mast Out in 2019

* Immucell Corp - U.S. FDA approval for co's product Mast Out anticipated in 2019, allowing for two, six-month reviews of cmc technical section by FDA Source text for Eikon: Further company coverage:

Oct 11 2016

More From Around the Web

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $63.60 +0.10
Pfizer Inc. (PFE.N) $34.43 -0.04
Eli Lilly and Co (LLY.N) $84.74 +0.38

Earnings vs. Estimates

No consensus analysis data available.